# A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

> **NCT00696657** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 415 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** liraglutide
- **DRUG:** liraglutide

## Key facts

- **NCT ID:** NCT00696657
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-03
- **Primary completion:** 2009-02-05
- **Final completion:** 2009-02-05
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696657, "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00696657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*